Recommendations for a public health approach
2010 revision
UNAIDS/99.31E (English original, June 1999)
1st revision, April 2000
National Guidelines for HIV & AIDS Care and Treatment (5th Edition)
AIDSTAR-One | CASE STUDY SERIES November 2012
Summary Report
Accessed: 19.10.2019
Participant Manual September 2009
PLOS Medicine | DOI:10.1371/journal.pmed.1002088 August 23, 2016
This fourth progress report November 2020 of the Global HIV Prevention Coalition reviews the progress in the 28 focus countries and complements the three previous progress reports. This report describes key developments in 2019–2020, identifies challenges and opportunities (including those associa...ted with the COVID-19 pandemic) and outlines priorities for the years ahead. It is divided into two main sections.
more
Recency assays use one or more biomarkers to identify whether HIV infection in a person is recent (usually within a year or less) or longstanding. Recency assays have been used to estimate incidence in representative cross-sectional surveys and in epidemiological studies to better understand the pat...terns and distributions of new and longstanding HIV infections.
This technical guidance outlines best practices regarding the appropriate use of HIV recency assays for surveillance purposes and updates 2011 technical guidance from the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) on the use of HIV recency assays.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
China and Eurasia Forum Quarterly, Volume 6, No. 3 (2008) p. 101-128 © Central Asia-Caucasus Institute & Silk Road Studies Program
ISSN: 1653-4212
Supplement to the 2016 consolidated Guidelines on the use of antiretroviral drugs for Treating and Preventing HIV infection
HIV Treatment